POS1500 ALL-CAUSE MORTALITY IN A SYSTEMIC LUPUS ERYTHEMATOSUS COHORT

Background Multiple studies have documented that patients with SLE a higher all-cause mortality. Active disease contributes to early deaths later more likely due cardiovascular and malignancy. Objectives In this study we present the pattern of mortality in single long-term, prospective cohort using death certificates document cause death. Methods The consists 2,238 (92% female, 52% Caucasian, 39% African American) 92% from Maryland surrounding states (MD 71%, VA 9%, PA 7%, DE 3%, WV 1%, DC 1%). Death records for 1,288 lost follow up prior 2020 were obtained National Index (NDI) at Center Disease Control (Atlanta, GA). NDI identified 11,369 1985 2019 as possible matches based on name, gender, race, date birth. Primary secondary causes provided best match each patient. CDC classifications ICD10 ICD9 codes. Lupus was if code M32.X or L93.0, 695.X 710.0 listed record. There 207 by matching data elements certificate reported family. Analysis these following set criteria additional remaining 1,079 up: 1) occurred after patient up; 2) least six out seven sent matched those record; 3) EITHER lupus record OR state residence Using criteria, an 297 found (Table 1). Results leading primary were: (n=116, 23%), (n=114, cancer (n=74, 15%), infection (n=66, 13%), other (n=55, 11%), respiratory (n=28, 6%), accidental (n=17, 3%), renal (n=9, 2%) gastrointestinal (n=8, 2%). significantly younger age (p-values less than 0.05 paired t-tests; Figure Americans died compared Caucasians (50 ± 15 years vs 58 16 years, p<0.001). had proportion infections (p=0.0017 Likelihood ratio test). Conclusion average 55 all (compared life expectancies >80 females US), certificates. Cancer third fourth Only common Caucasians. Table 1 – Matching Criteria Records Date Lost Follow Up Match = Cause State Family Reported Deaths Additional Total Y 7 115 99 214 N 70 143 213 3 12 6 9 10 39 49 0 Totals 504 : Age versus REFERENCES: NIL. Acknowledgements: Disclosure Interests Michelle A Petri Consultant of: MP is consultant Alexion, Amgen, AnaptysBio, Argenx, AstraZeneca, Aurinia, Biogen, Caribou Biosciences, CVS Health, EMD Serono, Eli Lilly, Emergent Biosolutions, GSK, IQVIA, Janssen, Kira Pharmaceuticals, MedShr, Sanofi SinoMab, Grant/research support from: received grant Exagen, Thermofisher, AstraZeneca Joseph Levy: None declared, Urbano Sbarigia Shareholder US employee Janssen Pharmaceutica NV, which wholly owned subsidiary Johnson & Johnson, owns stock options, Employee Daniel Goldman: declared.